<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35064780</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical and translational medicine</Title><ISOAbbreviation>Clin Transl Med</ISOAbbreviation></Journal><ArticleTitle>A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e657</StartPage><MedlinePgn>e657</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e657</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ctm2.657</ELocationID><Abstract><AbstractText>ALS is a fatal untreatable disease involving degeneration of motor neurons. &#x39c;ultiple causative genes encoding proteins with versatile functions have been identified indicating that diverse biological pathways lead to ALS. Chemical entities still represent a promising choice to delay ALS progression, attenuate symptoms and/or increase life expectancy, but also gene-based and stem cell-based therapies are in the process of development, and some are tested in clinical trials. Various compounds proved effective in transgenic models overexpressing distinct ALS causative genes unfortunately though, they showed no efficacy in clinical trials. Notably, while animal models provide a uniform genetic background for preclinical testing, ALS patients are not stratified, and the distinct genetic forms of ALS are treated as one group, which could explain the observed discrepancies between treating genetically homogeneous mice and quite heterogeneous patient cohorts. We suggest that chemical entity-genotype correlation should be exploited to guide patient stratification for pharmacotherapy, that is administered drugs should be selected based on the ALS genetic background.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Clinical and Translational Medicine published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pampalakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2119-4292</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology - Pharmacognosy, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology - Pharmacognosy, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zingkou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vekrellis</LastName><ForeName>Kostas</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biomedical Research Foundation, Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotiropoulou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1876</GrantID><Agency>Hellenic Foundation for Research and Innovation (HFRI) and General Secretariat for Research and Innovation (GSRI)</Agency><Country/></Grant><Grant><GrantID>T1EDK-03884</GrantID><Agency>BIOLUMINPD</Agency><Country/></Grant><Grant><GrantID>NSRF 2014-2020</GrantID><Agency>Competitiveness, Entrepreneurship and Innovation</Agency><Country/></Grant><Grant><Agency>Greece and the European Union (European Regional Development Fund)</Agency><Country/></Grant><Grant><Agency>Research Committee of the University of Patras</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Med</MedlineTA><NlmUniqueID>101597971</NlmUniqueID><ISSNLinking>2001-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000599">Amino Acids, Diamino</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087522">Cyanobacteria Toxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>108SA6URTV</RegistryNumber><NameOfSubstance UI="C001824">beta-N-methylamino-L-alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000599" MajorTopicYN="N">Amino Acids, Diamino</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087522" MajorTopicYN="N">Cyanobacteria Toxins</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029784" MajorTopicYN="N">Cycas</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">animal models</Keyword><Keyword MajorTopicYN="N">chemogenomics</Keyword><Keyword MajorTopicYN="N">disease heterogeneity</Keyword><Keyword MajorTopicYN="N">small molecules</Keyword><Keyword MajorTopicYN="N">stratification</Keyword></KeywordList><CoiStatement>The authors do not have conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>8</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35064780</ArticleId><ArticleId IdType="pmc">PMC8783349</ArticleId><ArticleId IdType="doi">10.1002/ctm2.657</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. New Engl J Med. 2017;377(2):162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777&#x2010;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitropoulos K, Katsila T, Patrinos GP, Pampalakis G. Multi&#x2010;omics for biomarker discovery and target validation in biofluids for amyotrophic lateral sclerosis diagnosis. OMICS. 2018;22(1):52&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29356625</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampalakis G, Mitropoulos K, Xiromerisiou G, et&#xa0;al. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis. Hum Mutat. 2019;40(4):361&#x2010;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">30556231</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta&#x2010;analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540&#x2010;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et&#xa0;al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Salomone S, D&#x2019; Agata V, Conforti FL, Cavallaro S. From multi&#x2010;omics approaches to precision medicine in amyotrophic lateral sclerosis. Front Neurosci. 2020;14:577755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7661549</ArticleId><ArticleId IdType="pubmed">33192262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, et&#xa0;al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Reports. 2019;29(5):1164&#x2010;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Morello G, Spampinato AG, et&#xa0;al. Omics&#x2010;based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS. Ageing Res Rev. 2020;62:101121.</Citation><ArticleIdList><ArticleId IdType="pubmed">32653439</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733&#x2010;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Savelieff MG, Sakowski SA, Feldman EL. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs. 2019;28(6):525&#x2010;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Ciotti C, Cohen&#x2010;Tannoudji M, Biferi MG. Gene therapy for ALS&#x2010;a perspective. Int J Mol Sci. 2019;20(18):4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Mareljic N, Michaelsen M, et&#xa0;al. Active poly&#x2010;GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. EMBO Mol Med. 2020;12(2):e10919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7005532</ArticleId><ArticleId IdType="pubmed">31858749</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Vance C, Scotter EL. Antisense oligonucleotide therapies for amyotrophic lateral sclerosis: existing and emerging targets. Int J Biochem Cell Biol. 2019;110:149&#x2010;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">30904737</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et&#xa0;al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet. 2004;5(4):262&#x2010;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">15131650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2010;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2010;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangelsdorf I, Walach H, Mutter J. Healing of amyotrophic lateral sclerosis: a case report. Complement Med Res. 2017;24(3):175&#x2010;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">28641283</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Bush AI. Metals and Alzheimer's disease: how far have we come in the clinic? J Alzheimers Dis. 2018;62(3):1369&#x2010;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870044</ArticleId><ArticleId IdType="pubmed">29562528</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos PM, Vesterberg O, Syversen T, Flaten TP, Nordberg M. Metal concentrations in cerebrospinal fluid and blood plasma form patients with amyotrophic lateral sclerosis. Biol Trace Elem Res. 2014;151(2):159&#x2010;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">23225075</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003;100(23):13380&#x2010;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263822</ArticleId><ArticleId IdType="pubmed">14612559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian KW, Jiang H, Wang BB, Zhang F, Han S. Intravenous injection of l&#x2010;BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson&#x2010;dementia complex. Toxicol Res (Camb). 2015;5(1):79&#x2010;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060832</ArticleId><ArticleId IdType="pubmed">30090328</ArticleId></ArticleIdList></Reference><Reference><Citation>Monson CS, Banack SA, Cox PA. Conservation implications of Chamorro consumption of flying foxes as a possible cause of amyotrophic lateral sclerosis&#x2010;parkinsonism dementia complex in Guam. Conserv Biol. 2003;17(3):678&#x2010;686.</Citation></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et&#xa0;al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264(5166):1772&#x2010;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Liu Z. Opportunities for neuroprotection in ALS using cell death mechanism rationales. Drug Discovery Today. 2004;1(2):135&#x2010;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT&#x2010;1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73&#x2010;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Tortarolo M, Suchak SK, et&#xa0;al. Transgenic SOD1G93A mice develop reduced GLT&#x2010;1 in spinal cord without alteration in cerebrospinal fluid glutamate levels. J Neurochem. 2001;79(4):737&#x2010;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">11723166</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Lai L, Butchbach ME, et&#xa0;al. Increased expression of the glial glutamate transporter EAAT2 modulates excitoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003;12(19):2519&#x2010;2532.</Citation><ArticleIdList><ArticleId IdType="pubmed">12915461</ArticleId></ArticleIdList></Reference><Reference><Citation>Contestabile A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr Med Chem. 2011;18(36):5655&#x2010;5665.</Citation><ArticleIdList><ArticleId IdType="pubmed">22172070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg MC, Halang L, Woods I, Coughlan KS, Prehn JHM. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5&#x2010;6):438&#x2010;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Limpert AS, Mattmann ME, Cosford NDP. Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis. Beilstein J Org Chem. 2013;9:717&#x2010;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3678841</ArticleId><ArticleId IdType="pubmed">23766784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, et&#xa0;al. Efficacy and safety of ceftriaxone for amyotrophic lateral sclerosis: results of a multi&#x2010;stage, randomized, double&#x2010;blind, placebo&#x2010;controlled, phase 3 study. Lancet Neurol. 2014;13(11):1083&#x2010;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Patel S, Regan MR, et&#xa0;al. Beta&#x2010;lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LG. Improvement of patient with amyotrophic laterals sclerosis given ceftriaxone. Lancet. 1992;339(8806):1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">1350828</ArticleId></ArticleIdList></Reference><Reference><Citation>Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26117714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Petri S, Kipiani K, et&#xa0;al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006;26(9):2467&#x2010;2473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793668</ArticleId><ArticleId IdType="pubmed">16510725</ArticleId></ArticleIdList></Reference><Reference><Citation>Neymotin A, Petri S, Calingasan NY, et&#xa0;al. Lenalidomide (Revlimid&#xae;) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2009;220(1):191&#x2010;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979314</ArticleId><ArticleId IdType="pubmed">19733563</ArticleId></ArticleIdList></Reference><Reference><Citation>Stommel EW, Cohen JA, Fadul CE, et&#xa0;al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):393&#x2010;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820489</ArticleId><ArticleId IdType="pubmed">19922130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Dequen F, Soucy G, Julien JP. Absence of tumor necrosis factor&#x2010;&#x3b1; does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci. 2006;26(44):11397&#x2010;11402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674545</ArticleId><ArticleId IdType="pubmed">17079668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons&#x2010;O'Brien E, Vogelsang G. Thalidomide&#x2010;induced neuropathy. Neurology. 2002;59(12):1872&#x2010;1875.</Citation><ArticleIdList><ArticleId IdType="pubmed">12499476</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre CD, Zambello R, Cacciavillani M, et&#xa0;al. Lenalidomide long&#x2010;term neurotoxicity: clinical and neurophysiologic prospective study. Neurology. 2016;87(11):1161&#x2010;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">27534712</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoechel TR, Tucker AD, Robinson CM, et&#xa0;al. Regulatory roles of the N&#x2010;terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry. 2006;45(28):402&#x2010;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401071</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, Cassina A, Mart&#xed;nez&#x2010;Palma L, et&#xa0;al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motol performance in inherited amyotrophic lateral sclerosis. PLoS One. 2012;7(4):e34776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318006</ArticleId><ArticleId IdType="pubmed">22509356</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunyach C, Michaud M, Arnoux T, et&#xa0;al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology. 2012;62(7):2346&#x2010;2352.</Citation><ArticleIdList><ArticleId IdType="pubmed">22369784</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Lacomblez L, Abitbol JL, et&#xa0;al. Mitotarget study group. A phase II&#x2010;III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21(3):529&#x2010;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P&#x2010;MR spectroscopy in patients with mitochondrial cytopathies. Biofactors. 1999;9(2&#x2013;4):253&#x2010;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">10416038</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998;95(15):8892&#x2010;8897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21173</ArticleId><ArticleId IdType="pubmed">9671775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Thompson JL, Levy G, et&#xa0;al. QALS study group. QALS study group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235&#x2010;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ari C, Poff AM, Held HE, et&#xa0;al. Metabolic therapy with Deanna Protocol supplementation delays disease progression and extends survival in amyotrophic lateral sclerosis (ALS) mouse model. PLoS One. 2014;9(7):e103526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111621</ArticleId><ArticleId IdType="pubmed">25061944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Cutting FB, Zhai P, et&#xa0;al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147&#x2010;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">8967745</ArticleId></ArticleIdList></Reference><Reference><Citation>Graf M, Ecker D, Horowski R, et&#xa0;al. German vitamin E/ALS Study Group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add&#x2010;on therapy to riluzole: results of a placebo&#x2010;controlled double&#x2010;blind study. J Neural Transm. 2005;112(5):649&#x2010;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517433</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, Kiaei M, Damiano M, et&#xa0;al. Cell&#x2010;permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2006;98:1141&#x2010;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16895581</ArticleId></ArticleIdList></Reference><Reference><Citation>Youdim MBH, Gross A, Finberg JPM. Rasagiline (N&#x2010;propargyl&#x2010;1R(+)&#x2010;aminoindan): a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132(2):500&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572573</ArticleId><ArticleId IdType="pubmed">11159700</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2014;251(19):1080&#x2010;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchi Z, Wang Y, Moore D, et&#xa0;al.; Western ALS (WALS) Rasagiline Study Group. A multi&#x2010;center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2010;6):345&#x2010;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610861</ArticleId><ArticleId IdType="pubmed">25832828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010;13(12):911&#x2010;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">21154151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, Morris JK. New therapeutics to modulate mitochondrial function in neurodegenerative disorders. Curr Pharm Des. 2017;23(5):731&#x2010;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5466080</ArticleId><ArticleId IdType="pubmed">28034353</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Owusu MA, Hughes I, Katz M, Broadley S, Sabet A. Effects of cannabinoids in amyotrophic lateral sclerosis (ALS) murine models: a systematic review and meta&#x2010;analysis. J Neurochem. 2019;149:284&#x2010;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">30520038</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo&#x2010;Porras F, Garc&#xed;a&#x2010;Toscano L, Rodr&#xed;guez&#x2010;Cueto C, Santos&#x2010;Garc&#xed;a I, de Lago E, Fernandez&#x2010;Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP&#x2010;43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br J Pharmacol. 2019;176:1585&#x2010;1600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Broadley S, Bedlack R, Russo E, Sabet A. Study protocol for a randomized, double&#x2010;blind, placebo&#x2010;controlled study evaluating the Efficacy of cannabis&#x2010;based Medicine extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. BMJ Open. 2019;9:e029449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858175</ArticleId><ArticleId IdType="pubmed">31719072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeldich E, Chen CD, Boden E, et&#xa0;al. Klotho is neuroprotective in the superoxide dismutase (SOD1G93A) mouse models of ALS. J Mol Neurosci. 2019;69(2):264&#x2010;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008951</ArticleId><ArticleId IdType="pubmed">31250273</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ, Fancelli D, Wong M, et&#xa0;al. GNX&#x2010;4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271619</ArticleId><ArticleId IdType="pubmed">25565966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange DJ, Shahbazi M, Silani V, et&#xa0;al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2017;81(6):837&#x2010;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair JR, Boggio KJ, Petsko GA, Ringe D, Agar JN. Strategies for stabilizing superoxide dismutase (SOD1): the destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2010;107(50):21394&#x2010;21399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang CJ, Chang YC, Chang HC, et&#xa0;al. Derlin&#x2010;1 regulates mutant VCR&#x2010;linked pathogenesis and endoplasmic reticulum stress&#x2010;induced apoptosis. PLoS Genet. 2014;10(9):e1004675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4177747</ArticleId><ArticleId IdType="pubmed">25255315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuburaya N, Homma K, Higuchi T, et&#xa0;al. A small&#x2010;molecule inhibitor of SOD1&#x2010;Derlin 1 ameliorates pathology in an ALS mouse model. Nat Commun. 2018;9(1):2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039432</ArticleId><ArticleId IdType="pubmed">29991716</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai I, Toichi K, Tokuda E, Mukaiyama A, Akiyama S, Furukawa Y. Screening of drugs inhibiting in vitro oligomerization of Cu/Zn&#x2010;superoxide dismutase with a mutation causing amyotrophic lateral sclerosis. Front Mol Biosci. 2016;3:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977284</ArticleId><ArticleId IdType="pubmed">27556028</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Nandar W, Neely EB, Simmons Z, Connor JR. Statins accelerate disease progression and shorten survival in SOD1 mice. Muscle Nerve. 2016;54(2):284&#x2010;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5848093</ArticleId><ArticleId IdType="pubmed">26799243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223&#x2010;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianforcaro A, Hamadeh MJ. Vitamin D as a potential therapy in amytrophic lateral sclerosis. CNS Neurosci Ther. 2014;20(2):101&#x2010;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493003</ArticleId><ArticleId IdType="pubmed">24428861</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam C, Barrett MJ, Imperato T, MacGowan DJL, Scelsa S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2013;20(11):1550&#x2010;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">23815870</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Passaniti C, et&#xa0;al. Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS). Eur J Clin Nutr. 2020;74(1):167&#x2010;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">31197218</ArticleId></ArticleIdList></Reference><Reference><Citation>Libonati L, Onesti E, Gori MC, et&#xa0;al. Vitamin D in amyotrophic lateral sclerosis. Funct Neurol. 2017;32(1):35&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505528</ArticleId><ArticleId IdType="pubmed">28380322</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper MJ, Wright GSA, Barbieri L, et&#xa0;al. The cysteine&#x2010;reactive small molecule ebselen facilitates effective SOD1 maturation. Nat Commun. 2018;9(1):1693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ampornadai K, Rogers M, Watanabe S, Yamanaka K, O'Neill PM, Hasnain SS. Novel selenium&#x2010;based compounds with therapeutic potential for SOD1&#x2010;linked amyotrophic lateral sclerosis. EBioMedicine. 2020;59:102980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456458</ArticleId><ArticleId IdType="pubmed">32862101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton JB, Mercer SW, Lim NK, et&#xa0;al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep. 2017;7:42292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BR, Lim NKH, McAllum EJ, et&#xa0;al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2014;34(23):8021&#x2010;8031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhao KT, Fox SG, et&#xa0;al. Tertiary amine pyrazolones and their salts as inhibitors of mutant superoxide dismutase 1&#x2010;dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2015;58(15):5942&#x2010;5949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4537347</ArticleId><ArticleId IdType="pubmed">26186011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Benmohamed R, Arvanites AC, et&#xa0;al. Arylsuflanyl pyrazolones block mutant SOD1&#x2010;G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg Med Chem. 2011;19(1):613&#x2010;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014451</ArticleId><ArticleId IdType="pubmed">21095130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Benmohamed R, Kim J, et&#xa0;al. ADME&#x2010;guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2012;55(1):515&#x2010;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8182972</ArticleId><ArticleId IdType="pubmed">22191331</ArticleId></ArticleIdList></Reference><Reference><Citation>Trippier PC, Zhao KT, Fox SG, et&#xa0;al. Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. ACS Chem Neurosci. 2014;5(9):823&#x2010;829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176317</ArticleId><ArticleId IdType="pubmed">25001311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A, Spiller KJ, Towne C, et&#xa0;al. Neuronal matrix metalloproteinase&#x2010;9 is a determinant of selective neurodegeneration. Neuron. 2014;81(2):333&#x2010;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015650</ArticleId><ArticleId IdType="pubmed">24462097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Kipiani K, Calingasan NY, et&#xa0;al. Matrix metalloproteinase&#x2010;9 regulates TNF&#x2010;alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2007;205(1):74&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362932</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Khan T, Dominique MA, et&#xa0;al. YReduction of matrix metalloproteinase 9 (MMP&#x2010;9) protects motor neurons from TDP&#x2010;43&#x2010;triggered death in rNLS8 mice. Neurobiol Dis. 2019;124:133&#x2010;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7053168</ArticleId><ArticleId IdType="pubmed">30458231</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Wu JW, Myeku N, et&#xa0;al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8(4):609&#x2010;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3405840</ArticleId><ArticleId IdType="pubmed">22361619</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A, Patten SA, Ciura S, et&#xa0;al. Methylene blue protects against TDP&#x2010;43 and FUS neuronal toxicity in C. elegans and D. rerio . PLOS One. 2012;7(7):e42117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407135</ArticleId><ArticleId IdType="pubmed">22848727</ArticleId></ArticleIdList></Reference><Reference><Citation>Audet JN, Soucy G, Julien JP. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience. 2012;209:136&#x2010;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">22230045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lougheed R, Turnbul J. Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS One. 2011;6(10):e23141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188547</ArticleId><ArticleId IdType="pubmed">21998625</ArticleId></ArticleIdList></Reference><Reference><Citation>Das I, Krzyzosiak A, Schneider K, et&#xa0;al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348:239&#x2010;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490275</ArticleId><ArticleId IdType="pubmed">25859045</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Popko B, Tixier E, Roos RPG. which enhances the unfolded protein response, ameliorates mutant SOD1&#x2010;induced amyotrophic lateral sclerosis. Neurobiol Dis. 2014;71:317&#x2010;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179984</ArticleId><ArticleId IdType="pubmed">25134731</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HQ, Ren M, Jiang HZ, et&#xa0;al. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic laterals sclerosis. Neuroscience. 2014;277:132&#x2010;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24699224</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B, Brogden RN, Heel RC, Speight TM, Avery GSG. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983;26(3):212&#x2010;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">6352237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecozzi VJ, Berman DE, Simoes S, et&#xa0;al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol. 2014;10(6):443&#x2010;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="pubmed">24747528</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzio L, Sirtori R, Gornati D, et&#xa0;al. Retromer stabilization results in neuroprotection in a model of amyotrophic lateral sclerosis. Nat Commun. 2020;11(1):3848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395176</ArticleId><ArticleId IdType="pubmed">32737286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieran D, Kalmar B, Dick JRT, Riddoch&#x2010;Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402&#x2010;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Edet&#x2010;Amana E, Greensmith L. Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1&#x2010;G93A mouse model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(4):378&#x2010;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">22591194</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et&#xa0;al. Randomized, double&#x2010;blind, placebo&#x2010;controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565&#x2010;e574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et&#xa0;al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron. 2011;72(2):245&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et&#xa0;al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron. 2011;72(2):257&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bienek KF, Gendron TF, et&#xa0;al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77(4):639&#x2010;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, et&#xa0;al. Antisense transcripts of the expanded C9ORF62 hexanucleotide repeat form nuclear RNA loci and undergo repeat&#x2010;associated non&#x2010;ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126(6):829&#x2010;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Gr&#xe4;sser FA, et&#xa0;al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126(6):881&#x2010;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, et&#xa0;al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2010;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Braems E, Swinnen B, Van Den Bosch L. C9orf72 loss&#x2010;of&#x2010;function: a trivial, stand&#x2010;alone or additive mechanism in C9 ALS/FTD? Acta Neuropathol. 2020(5):625&#x2010;643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547039</ArticleId><ArticleId IdType="pubmed">32876811</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Moens TG, Isaacs AM. Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies. EMBO Mol Med. 2017;9(7):853&#x2010;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524429</ArticleId><ArticleId IdType="pubmed">28533210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH, et&#xa0;al. Poly&#x2010;GP in cerebrospinal fluid links C9orf72&#x2010;associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med. 2017;9(7):859&#x2010;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z, Zhang Y, Gendron TF, et&#xa0;al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)&#x2010;associated defects in c9FTD/ALS. Neuron. 2014;83(5):1043&#x2010;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone R, Balendra R, Moens TG, et&#xa0;al. G&#x2010;quadruplex&#x2010;binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med. 2018;10(1):22&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760849</ArticleId><ArticleId IdType="pubmed">29113975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamiri B, Reddy K, Macgregor RB Jr, Pearson CE. TMPyP4 porphyrin distorts RNA G&#x2010;quadruplex structures of the disease&#x2010;associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA&#x2010;binding proteins. J Biol Chem. 2014;289(8):4653&#x2010;4659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931028</ArticleId><ArticleId IdType="pubmed">24371143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZF, Ursu A, Childs&#x2010;Disney JL, et&#xa0;al. The hairpin form of r(G(4)C(2))(exp) in c9ALS/FTD is repeat&#x2010;associated non&#x2010;ATG translated and a target for bioactive small molecules. Cell Chem Biol. 2019;26(2):179&#x2010;190. e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386614</ArticleId><ArticleId IdType="pubmed">30503283</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz A, Marques JP, Oertig I, Maharjan N, Saxena S. Emerging perspectives on dipeptide repeat proteins in C9ORF72 ALS/FTD. Front . Cell Neurosci. 2021;15:637548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7930069</ArticleId><ArticleId IdType="pubmed">33679328</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et&#xa0;al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313&#x2010;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats KA, Sea HC, Sahimi A, et&#xa0;al. Small molecule inhibition of PIKFYVE kinase rescues gain&#x2010; and loss&#x2010;of&#x2010;function C9ORF72 ALS/FTD disease processes in vivo. bioRxiv. 10.1101/685800</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/685800</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YF, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang HT. Antidepressant&#x2010; and anxiolytic&#x2010;like effects of the phosphodiesterase&#x2010;4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein&#x2010;mediated neurogenesis in the hippocampus. Neuropsychopharmacology. 2009;34(11):2404&#x2010;2419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743762</ArticleId><ArticleId IdType="pubmed">19516250</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, LaClair KD, Riemenschneider H, et&#xa0;al. Cell&#x2010;to&#x2010;cell transmission of C9orf72 poly&#x2010;(Gly&#x2010;Ala) triggers key features of ALS/FTD. EMBO J. 2020;39(8):e102811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156967</ArticleId><ArticleId IdType="pubmed">32175624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer NJ, Haney MS, Morgens DW, et&#xa0;al. CRISPR&#x2010;Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide&#x2010;repeat&#x2010;protein toxicity. Nat Genet. 2018;50(4):603&#x2010;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893388</ArticleId><ArticleId IdType="pubmed">29507424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Mestre AA, et&#xa0;al. C9ORF72 GGGGCC repeat&#x2010;associated non&#x2010;AUG translation is upregulated by stress through eIF2&#x3b1; phosphorylation. Nat Commun. 2018;9(1):51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754368</ArticleId><ArticleId IdType="pubmed">29302060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Jansen&#x2010;West K, Xu YF, et&#xa0;al. Aggregation&#x2010;prone c9FTD/ALS poly(GA) RAN&#x2010;translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128(4):505&#x2010;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, et&#xa0;al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88(5):902&#x2010;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, Sanelli T, Dib SL. RNA targets of TDP&#x2010;43 identified by UV&#x2010;CLIP are deregulated in ALS. Mol Cell Neurosci. 2011;47(3):167&#x2010;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">21421050</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier&#x2010;Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 2012;1462:3&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707312</ArticleId><ArticleId IdType="pubmed">22444279</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, et&#xa0;al. TDP&#x2010;43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111(4):1051&#x2010;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, et&#xa0;al. RNA binding antagonizes neurotoxic phase transitions of TDP&#x2010;43. Neuron. 2019;102(2):321&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset&#x2010;Rosa F, Lu S, Yu H, et&#xa0;al. Cytoplasmic TDP&#x2010;43 de&#x2010;mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP&#x2010;43, and cell death. Neuron. 2019;102(2):339&#x2010;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR. The debated toxic role of aggregated TDP&#x2010;43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142(5):1176&#x2010;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et&#xa0;al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, et&#xa0;al. Truncated stathmin&#x2010;2 is a marker of TDP&#x2010;43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080&#x2010;6092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, et&#xa0;al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:658226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033025</ArticleId><ArticleId IdType="pubmed">33841129</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP&#x2010;43 proteinopathy with drug and drug&#x2010;like small molecules. Br J Pharmacol. 2021;178(6):1298&#x2010;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose P, Tremblay E, Maois C, et&#xa0;al. The novel small molecule TRVA242 stabilizes neuromuscular junction defects in multiple animal models of amyotrophic lateral sclerosis. Neurotherapeutics. 2019;16(4):1149&#x2010;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985319</ArticleId><ArticleId IdType="pubmed">31342410</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q, Wang H, Hao Z. TDP&#x2010;43 loss of function increases TFEB activity and blocks autophagosome&#x2010;lysosome fusion. EMBO J. 2016;35(2):121&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718457</ArticleId><ArticleId IdType="pubmed">26702100</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, Oddo S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C&#x2010;terminal fragment of TDP&#x2010;43. Hum Mol Genet. 2015;24(16):4625&#x2010;4635.</Citation><ArticleIdList><ArticleId IdType="pubmed">26002100</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K. Zarogoulidis, K. mTOR pathway: a current, up&#x2010;to&#x2010;date mini&#x2010;review. Oncol Lett. 2014;8(6):2367&#x2010;2370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214394</ArticleId><ArticleId IdType="pubmed">25360163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Guo BS, Liu YC. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA&#x2010;binding protein 43. Proc Natl Acad Sci USA. 2012;109(37):15024&#x2010;15029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CW, Lin MJ, Shen CK. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS&#x2010;TDP. J Neurogenet. 2015;29(2&#x2010;3):59&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26219309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li L, Chen S, et&#xa0;al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7(4):412&#x2010;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Serio A, Arjun A. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol. 2014;10(8):677&#x2010;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Tosat&#x2010;Bitrian C, Nozal V, Nagaraj S, Martin&#x2010;Requero A, Martinez A. TDP&#x2010;43: a key therapeutic target beyond amyotrophic lateral sclerosis. ACS Chem Neurosci. 2019;10(3):1183&#x2010;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyburn L, Hebron ML, Smith J, et&#xa0;al. Tyrosine kinase inhibition reverses TDP&#x2010;43 effects on synaptic protein expression, astrocytic function and amino acid dis&#x2010;homeostasis. J Neurochem. 2016;139(4):610&#x2010;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">27507246</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, et&#xa0;al. The Src/c&#x2010;Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(391):eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado IG, Redondo M, Bello ML, et&#xa0;al. Protein kinase CK&#x2010;1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014;57(6):275&#x2010;2772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C, Salado IG, de la Encarnaci&#xf3;n A, et&#xa0;al. Targeting TDP&#x2010;43 phosphorylation by Casein Kinase&#x2010;1&#x3b4; inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol Neurodegener. 2016;11(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4852436</ArticleId><ArticleId IdType="pubmed">27138926</ArticleId></ArticleIdList></Reference><Reference><Citation>Posa D, Mart&#xed;nez&#x2010;Gonz&#xe1;lez L, Bartolom&#xe9; F, et&#xa0;al. Recapitulation of pathological TDP&#x2010;43 features in immortalized lymphocytes from sporadic ALS patients. Mol Neurobiol. 2019;56(4):2424&#x2010;2432.</Citation><ArticleIdList><ArticleId IdType="pubmed">30030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP&#x2010;43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74(1):39&#x2010;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3775949</ArticleId><ArticleId IdType="pubmed">23424178</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D, James JL, Parker SJ, et&#xa0;al. Kinase inhibitor screening identifies cyclin&#x2010;dependent kinases and glycogen synthase kinase 3 as potential modulators of TDP&#x2010;43 cytosolic accumulation during cell stress. PLoS One. 2013;8(6):e67433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3694067</ArticleId><ArticleId IdType="pubmed">23840699</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JD, Lee P, Feiler MS, et&#xa0;al. A high&#x2010;content screen identifies novel compounds that inhibit stress&#x2010;induced TDP&#x2010;43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 2014;19(1):44&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A, Menzl J, Podolsky TC. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP&#x2010;43. Hum Mol Genet. 2015;24(6):1741&#x2010;1754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4381760</ArticleId><ArticleId IdType="pubmed">25432537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, et&#xa0;al.; GERP ALS Study Group. A randomized, double blind, placebo&#x2010;controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2017;7:e37885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Kitaoka S, Tsukita K, et&#xa0;al. Drug screening for ALS using patient&#x2010;specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145). 145ra104.</Citation><ArticleIdList><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, et&#xa0;al. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep. 2018;8(1):4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou&#x2010;Ajram C, et&#xa0;al. Nuclear egress of TDP&#x2010;43 and FUS occurs independently of exportin&#x2010;1/CRM1. Sci Rep. 2018;8(1):7084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Ca&#x11f;atay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP&#x2010;43 localization. Sci Rep. 2018;8(1):7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PT, Li&#xe9;vens JC, Wang SM, et&#xa0;al. Sigma&#x2010;1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Droshophila ALS/FTD models. Nat Commun. 2020;11(1):5580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7642387</ArticleId><ArticleId IdType="pubmed">33149115</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov TA, Epstein ML, Verbny MS, et&#xa0;al. Lack of Sigma&#x2010;1 receptor exacerbates ALS progression in mice. Neuroscience. 2013;240(14):129&#x2010;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665351</ArticleId><ArticleId IdType="pubmed">23458708</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero EN, Wang H, Mitra J, et&#xa0;al. TDP&#x2010;43/FUS in motor neuron disease: complexity and challenges. Prog Neurobiol. 2016;145&#x2013;146:78&#x2010;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5101148</ArticleId><ArticleId IdType="pubmed">27693252</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Drexler HCA, Wang J, et&#xa0;al. FUS pathology in ALS is linked to alterations in multiple ALS&#x2010;associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138(1):67&#x2010;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu HH, Jun MH, Min KJ, Jang DJ, Lee YS, Kim HK. Autophagy regulates amyotrophic lateral sclerosis&#x2010;linked fused in sarcoma&#x2010;positive stress granules in neurons. Neurobiol Aging. 2014;35(12):2822&#x2010;2831.</Citation><ArticleIdList><ArticleId IdType="pubmed">25216585</ArticleId></ArticleIdList></Reference><Reference><Citation>Soo KY, Halloran M, Sundaramoorthy V, et&#xa0;al. Rab1&#x2010;dependent ER&#x2010;Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP&#x2010;43 and FUS&#x2010;associated ALS. Acta Neuropathol. 2015;130(5):679&#x2010;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">26298469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et&#xa0;al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436&#x2010;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Doronzio PN, Marangi G, et&#xa0;al. Coexistence of variants in TBK1 and in other ALS&#x2010;related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging. 2019;84. 239.e9&#x2010;e239.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31000212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnard M, Mirtsos C, Suzuki S, et&#xa0;al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF&#x2010;kappaB&#x2010;dependent gene transcription. EMBO J. 2000;19(18):4976&#x2010;4985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314216</ArticleId><ArticleId IdType="pubmed">10990461</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieverding K, Ulmer J, Bruno C, et&#xa0;al. Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP&#x2010;43G298S transgenic mice. Exp Neurol. 2021;335:113496.</Citation><ArticleIdList><ArticleId IdType="pubmed">33038415</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Sieverding K, Bruno C, et&#xa0;al. Heterozygous Tbk1 loss has opposing effects in early and late stage of ALS in mice. J Exp Med. 2019;261(2):267&#x2010;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Jin T, Zhu H, et&#xa0;al. TBK1 suppresses RIPK1&#x2010;driven apoptosis and inflammation during development and in aging. Cell. 2018;174(6):1477&#x2010;1491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128749</ArticleId><ArticleId IdType="pubmed">30146158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Ofengeim D, Yuan J. Receptor&#x2010;interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19(8):553&#x2010;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362612</ArticleId><ArticleId IdType="pubmed">32669658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, et&#xa0;al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603&#x2010;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagi KS, Wu Z, Amaya J, et&#xa0;al. Meta&#x2010;analysis of genetic modifiers reveals candidate dysregulated pathways in amyotrophic lateral sclerosis. Neuroscience. 2019;396:A3&#x2010;A20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549511</ArticleId><ArticleId IdType="pubmed">30594291</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, Schoonaert L, Lemmens R, et&#xa0;al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18(9):1418&#x2010;1422.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Noberini R, Koolpe M, Peddibhotla S, et&#xa0;al. Small molecules can selectively inhibit ephrin bind EphA4 and EphA2 receptors. J Biol Chem. 2008;283(43):29461&#x2010;29472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570887</ArticleId><ArticleId IdType="pubmed">18728010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, De SK, Kulinich A, et&#xa0;al. Potent and selective EphA4 agonists for the treatment of ALS. Cell Chem Biol. 2017;24(3):293&#x2010;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling KK, Jackson M, Alkam D, et&#xa0;al. Antisense&#x2010;mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiol Dis. 2018;114:174&#x2010;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820074</ArticleId><ArticleId IdType="pubmed">29518482</ArticleId></ArticleIdList></Reference><Reference><Citation>Fil D, DeLoach A, Yadav S, et&#xa0;al. Mutant profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Hum Mol Genet. 2017;26(4):686&#x2010;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968635</ArticleId><ArticleId IdType="pubmed">28040732</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Jones AR, Sproviero W, et&#xa0;al. Meta&#x2010;analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915&#x2010;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez&#x2010;Lopez A, Gamez J, Syriani E, et&#xa0;al. CXC3R1 is a modifying gene of survival and progression in amyotrophic laterals sclerosis. PLoS One. 2014;9(5):e96528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4013026</ArticleId><ArticleId IdType="pubmed">24806473</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Hong K, Chen H, et&#xa0;al. Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis. Biol Chem. 2019;400(5):651&#x2010;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">30352020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski&#x2010;Kuhn M, Robinson M, Strupe J, et&#xa0;al. IL6 receptor 358Ala variant and trans&#x2010;signaling disease modifiers in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865852</ArticleId><ArticleId IdType="pubmed">31611269</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ripley B, Serada S, Naka T, Fujimoto M. Interleukin&#x2010;6 deficiency does not affect motor neuron disease caused by superoxide dismutase 1 mutation. PLOS One. 2016;11(4):e0153399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829212</ArticleId><ArticleId IdType="pubmed">27070121</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Mizwicki MT, Weitzman R, Magpantay L, Nishimoto N. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis. 2013;2(2):129&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703125</ArticleId><ArticleId IdType="pubmed">23844337</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfahad T, Nath A. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. 2013;99(2):180&#x2010;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723705</ArticleId><ArticleId IdType="pubmed">23707220</ArticleId></ArticleIdList></Reference><Reference><Citation>Westarp ME, Bartmann P, Rossler J, et&#xa0;al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport. 1993;4(6):819&#x2010;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">8394159</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;sener M, Hahn H, Kranz M, Heeney J, Rethwilm A. Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis. J Med Virol. 1998;48(3):222&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8801281</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):REVIEWS1017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC138943</ArticleId><ArticleId IdType="pubmed">11423012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer J, Harz C, Sanchez L, et&#xa0;al. Transcriptional profiling of HERV&#x2010;K(HML&#x2010;2) in amyotrophic lateral sclerosis and potential implications for expression of HML&#x2010;2 proteins. Mol Neurodegener. 2018;13(1):39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091006</ArticleId><ArticleId IdType="pubmed">30068350</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu L, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69(1):141&#x2010;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, et&#xa0;al. Human endogenous retrovirus&#x2010;K contributes to motor neuron disease. Sci Transl Med. 2015;7(307). 307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras&#x2010;Galindo R, Dube D, Fujinaga K, Kaplan MH, Markovitz DM. Susceptibility of human endogenous retrovirus type K to reverse transcriptase inhibitors. J Virol. 2017;91(23). e01309&#x2010;e01317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5686744</ArticleId><ArticleId IdType="pubmed">28931682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Li W, Parades D, Bianchet MA, Nath A. Inhibition of human endogenous retrovirus&#x2010;K by antiretroviral drugs. Retrovirology. 2017;14(1):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5361811</ArticleId><ArticleId IdType="pubmed">28330477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS. J Neurochem. 2008;107(2):339&#x2010;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">18673445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb HM, Sharp PS, Rahmani&#x2010;Kondori N, Wells J. Metformin treatment has no beneficial effect in a dose&#x2010;response survival study in the SOD1G93A mouse model of ALS and is harmful in female mice. PLoS One. 2011;6(9):e24189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Guo S, Bardhi O, et&#xa0;al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9ORF72 ALS/FTD mice. Proc Natl Acad Sci USA. 2020;117(31):18591&#x2010;18599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="pubmed">32690681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Crippa V, Cereda C, et&#xa0;al. Proteostasis and ALS: protocol for a phase II, randomized, double&#x2010;blind, placebo&#x2010;controlled, multicentre clinical trial for colchicine in ALS (Co&#x2010;ALS). BMJ Open. 2019;9(5):e028486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6549675</ArticleId><ArticleId IdType="pubmed">31152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Crippa V, D&#x2019; Agostino VG, Cristofani R, et&#xa0;al. Transcriptional induction of the heat shock protein B8 mediated the clearance of misfolded proteins responsible for motor neuron diseases. Sci Rep. 2016;6:22827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785366</ArticleId><ArticleId IdType="pubmed">26961006</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, Veldink JH, van der Tweel I, et&#xa0;al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437&#x2010;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Eijkemans MJC, Nikolakopoulos S, et&#xa0;al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J. 2019;20(2):220&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">31624333</ArticleId></ArticleIdList></Reference><Reference><Citation>Limanaqi F, Biagioni F, Ryskalin L, Busceti CL. Molecular mechanisms linking ALS/FTD and psychiatric disorders, the potential effects of lithium. Front Cell Neurosci. 2019;13:450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797817</ArticleId><ArticleId IdType="pubmed">31680867</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshtein H, Muhire A, L&#xe9;gar&#xe9; VP, et&#xa0;al. Efficacy of ciprofloxacin/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(10):1883&#x2010;1897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545590</ArticleId><ArticleId IdType="pubmed">32915525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rue L, Timmers M, Lenaerts A, et&#xa0;al. Reducing EphA4 before disease onset does not affect survival in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2019;9(1):14112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773754</ArticleId><ArticleId IdType="pubmed">31575928</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard JP, Maragakis NJ. Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res. 2015;1607:15&#x2010;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362997</ArticleId><ArticleId IdType="pubmed">25223906</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Fumagalli L, Prior R, Van Den Bosch L. Current advances and limitations in modeling ALS/FTD in a dish using induced pluripotent stem cells. Front Neurosci. 2017;11:671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733489</ArticleId><ArticleId IdType="pubmed">29326542</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoing MC, Burke D, Pamphlett R. Riluzole therapy for motor neurone disease: an early Australian experience (1996&#x2013;2002). J Clin Neurosci. 2006;13(1):78&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410201</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal&#x2010;Taboada JM, Pugliese M, Salvad&#xf3; M, G&#xe1;mez J, Mahy N, Rodr&#xed;guez MJ. KATP channel expression and genetic polymorphisms associated with progression and survival in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55(10):7962&#x2010;7972.</Citation><ArticleIdList><ArticleId IdType="pubmed">29492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PWJ, van Rheenen W, et&#xa0;al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>